The propofol infusion syndrome in infants and children: can we predict the risk?

Area of Science:

• Anesthesiology
• Critical Care Medicine
• Toxicology

Background:

• Propofol is a widely used anesthetic induction agent.
• Prolonged infusions for sedation are associated with serious complications.
• Initial reports focused on pediatric cases with severe metabolic disturbances.

Purpose of the Study:

• To review the emerging evidence linking prolonged propofol sedation to a specific syndrome.
• To highlight the clinical features and potential metabolic underpinnings of this adverse event.
• To discuss the implications for patient safety during extended propofol use.

Main Methods:

• Review of case reports and clinical data concerning propofol infusion syndrome.
• Analysis of clinical manifestations including myocardial failure, metabolic acidosis, and organ damage.
• Investigation of proposed metabolic explanations for the observed toxicity.

Main Results:

• A distinct syndrome associated with prolonged propofol sedation has become increasingly recognized.
• Key features include intractable myocardial failure, metabolic acidosis, lipaemic plasma, hepatic steatosis, and rhabdomyolysis.
• The syndrome affects both children and adults, with a high mortality rate.

Conclusions:

• Propofol infusion syndrome is a serious complication of prolonged sedation.
• Metabolic derangements are central to the pathophysiology of this syndrome.
• Dialysis is currently the only identified effective treatment for propofol infusion syndrome.